



**CM HOSPITALAR S.A.**

Publicly Traded Company

Corporate Taxpayer's ID (CNPJ/MF) 12.420.164/0001-57

Company's Registry (NIRE) 35.300.486.854

CVM Code 25682

ISIN: BRVVEOACNOR0

B3 Ticker: VVEO3

**MATERIAL FACT**

**Shares' Buyback Program**

**CM Hospitalar S.A. ("Viveo" or "Company")**, an ecosystem of companies specialized in each link of the health chain, in compliance with the provisions of article 157, of Law No. 6404, of December 15, 1976, in Resolution of the Securities and Exchange Commission ("**CVM**") No. 44, of August 23, 2021, and in CVM Instruction No. 567, of September 17, 2015 ("**CVM Instruction 567**"), informs its shareholders and the market in general, that the Board of Directors approved the opening of a share buyback program ("**Buyback Program**").

**Objective**

To comply with the Restricted Shares Granting Program, pursuant to the Long-Term Incentive Plan with Restricted Shares, approved by the Company's Extraordinary Shareholders' Meeting on March 17, 2021; and maximize the generation of shareholder's value, since in management's view, the current price of its shares does not reflect the real value of the Company.

**Outstanding shares and number of shares to be acquired**

The Company has a total of 286,123,360 shares and 115,680,492 shares on free-float and has no treasury shares. Viveo may acquire up to 5,784,024 common, book-entry, nominative shares with no par value, issued by the Company, which represents 5.00% of the free-float shares.

Total shares	286,123,360
Free-float shares	115,680,492
<b>Buyback</b>	<b>5,784,024</b>
% of total shares	<b>2.02%</b>
% of total free-float shares	<b>5.00%</b>

**Term and Resources for the Buyback Program**

The term of the Buyback Program will be 18 months, starting on January 21, 2022, and ending on July 21, 2023.

The purchase operations will be supported by the resources available in the profit reserve account, segregating the allocations to the reserves mentioned in Art. 7, §1, item I of ICVM Instruction 567.

**Brokers that can act as intermediaries**

ITAÚ CV S.A.

BTG PACTUAL CTVM S.A.

J.P. MORGAN CCMV S.A.

CREDIT SUISSE S.A. CTVM

Finally, Viveo reiterates its commitment to keep its shareholders and the market in general informed about the progress of this and any other matter of interest to the market.

Ribeirao Preto, January 20, 2022.

LEONARDO ALMEIDA BYRRO  
CEO and Investor Relations Officer  
**CM HOSPITALAR S.A.**